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Background: Several studies analyzed the associations of Vitamin D receptor (VDR) polymorphisms with urolithiasis
risk in different ethnic groups. However, the results were inconclusive. To evaluate a more precise estimation of the
relationship, a meta-analysis was performed.
Methods: Pubmed, EMBASE, Wanfang Database, China National Knowledge Infrastructure (CNKI) and Weipu
Database were searched. Data were extracted independently by two investigators. Odds ratios (ORs) with 95%
confidence intervals (CIs) were used to assess the strength of associations.
Results: Twenty-three case–control studies were included in this meta-analysis. Significant associations between
ApaI, BsmI, FokI, and TaqI polymorphisms and urolithiasis risk were observed. However, sensitivity analyses for BsmI
and FokI polymorphisms indicated that the results were not reliable and credible. In addition, there was a
significant association of the ApaI-TaqI haplotype with urolithiasis risk.
Conclusions: This meta-analysis suggested that ApaI and TaqI polymorphisms in VDR gene were associated with
urolithiasis risk.
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Urolithiasis is one of the most prevalent uronephrologic
disorders and affects approximately 10% of individuals
in western countries [1]. The incidence of urolithiasis is
increasing. For example, in the US the prevalence has
risen from 3.2% to 5.2% in just over two decades from
the mid-1970s to the mid-1990s [2]. Previous studies
evidenced the importance of genes in this disease. Stud-
ies of kidney stone-forming twins demonstrated a higher
concordance for kidney stones in monozygotic than in
dizygotic twins [3]. Additionally, a family history was
reported to increase the disease risk (2.57 times higher)
in males [4]. Thus, it is important to identify the gene
variants contributing to urolithiasis pathogenesis.
Recently, Elkoushy and coworkers found that patients
with urolithiasis had a high prevalence of inadequate
vitamin D [5]. Expression and nuclear activation of the
Vitamin D receptor (VDR) are necessary for the effects* Correspondence: drjianghong@163.com
†Equal contributors
1Department of Nephrology, the First People’s Hospital of Jingzhou City, the
First Hospital of Yangtze University, Jingzhou, Hubei Province 434000, China
Full list of author information is available at the end of the article
© 2013 Zhang et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orof vitamin D. Therefore, VDR was implicated in urolith-
iasis. In genetic hypercalciuric stone-forming (GHS) rats,
Yao et al. [6] found that VDR mRNA levels were higher
in kidney compared with wild-type controls. In addition,
Favus et al. [7] showed that the level of VDR in periph-
eral blood monocytes was twofold greater in male cal-
cium oxalate stone formers than in controls. Taken
together, these results suggested that VDR may play an
important role in the pathogenesis of urolithiasis.
The human VDR gene is located on chromosome
12q12-14. Four single nucleotide polymorphisms (SNPs)
of the VDR gene have been widely studied [8]. ApaI,
BsmI, and TaqI are located between the 8 and 9 exons in
the 3′-untranslated region (UTR), and shown to be in
strong linkage disequilibrium (LD) [9]. Another SNP is
the FokI, which is located at the translation starting
codon. Many studies investigated the associations be-
tween these polymorphisms of VDR gene and the risk of
urolithiasis [10-32]. However, the results were inconclu-
sive. The inconsistent results were possibly due to the
low statistical powers of individual studies. The method
of meta-analysis could provide a quantitative approachLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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topic. Therefore, we performed this meta-analysis to ad-
dress the precise relationship between the VDR gene vari-
ants and urolithiasis risk.
Methods
Publication search
We performed a systematic search of Pubmed, EMBASE,
Wanfang Database, China National Knowledge Infrastruc-
ture (CNKI) and Weipu Database to find relevant studies.
The search terms were used as follows: (urolithiasis or kid-
ney stone or kidney stone disease) and (Vitamin D receptor
or VDR) and (polymorphism or mutation or variant). Last
search was updated in October, 2012. No language restric-
tion was imposed. The reference lists of searched articles
and relevant reviews were all perused to find additional eli-
gible studies.
Inclusion and exclusion criteria
Two reviewers (Zhang and Nie) independently screened
titles and abstracts of all studies for relevancy. Disagree-
ments were resolved by discussion. Studies included in
this meta-analysis based on the following selection cri-
teria: (1) evaluation of the ApaI, BsmI, TaqI, and FokI
polymorphisms in VDR gene and urolithiasis risk, (2)
using a case–control design, and (3) genotype distribu-
tions in both cases and controls should be available for
estimating an odds ratio (OR) and 95% confidence inter-
val (CI).
Studies were excluded if one of the following existed:
(1) the VDR polymorphisms were not analyzed or the
outcome was not urolithiasis risk, (2) not case–control
studies, such as the design based on family or sibling
pairs, (3) not reported genotype frequencies or number,
(4) abstracts or reviews, and (5) non-clinical study. For
overlapping studies, the one with the largest sample size
was included.
Data extraction
The full manuscripts of eligible studies were reviewed by
two investigators (Zhang and Nie) independently. Any
discrepancy was resolved by discussion or a third author
(Jiang) would assess the articles. The following informa-
tion was collected from each study: the first author’s
name, year of publication, original country, ethnicity, age
group, hypercalciuria in the urolithiasis group, compos-
ition of stone, sample size, the polymorphisms in VDR
gene, genotyping method, and genotype number in cases
and controls. We contacted the corresponding authors if
more data was needed.
Quality assessment
The quality of the studies was assessed by two investiga-
tors (Zhang and Nie) independently. The predeterminedcriteria were modified from a previous review [33].
These scores were based on traditional epidemiological
considerations and genetic issues. Scores ranged from
zero (lowest) to ten (highest). Disagreement was settled
by discussion. Articles scoring < 5 were defined as low
quality, and those ≥ 5 were defined as high quality.
Statistical analysis
When the data from at least three similar studies were
available, meta-analysis was performed. The strength of
the associations between the ApaI, BsmI, FokI, and TaqI
polymorphisms and urolithiasis risk was measured by
ORs and 95% CIs. OR1, OR2, and OR3 were calculated
for the genotypes: 1) AA vs. aa (OR1), aA vs. aa (OR2),
and AA vs. aA (OR3) for the ApaI, 2) bb vs. BB (OR1),
bB vs. BB (OR2), and bb vs. bB (OR3) for the BsmI, 3) ff
vs. FF (OR1), fF vs. FF (OR2), and ff vs. fF (OR3) for the
FokI, and 4) tt vs. TT (OR1), tT vs. TT (OR2), and tt vs.
tT (OR3) for the TaqI, respectively. The statistical sig-
nificance of OR was analyzed by Z test. These pairwise
differences were used to indicate the most appropriate
genetic model as follows: if OR1 = OR3 ≠ 1 and OR2 = 1,
then a recessive model was suggested; if OR1 =OR2 ≠ 1
and OR3 = 1, then a dominant model was suggested; if
OR2 = 1/OR3 ≠ 1 and OR1 = 1, then a complete over-
dominant model was suggested; if OR1 > OR2 > 1 and
OR1 >OR3 > 1 (or OR1 < OR2 < 1 and OR1 <OR3 < 1),
then a codominant model was suggested [34,35]. Once
the best genetic model was identified, this model was
used to collapse the three genotypes into two groups
(except in the case of a codominant model) and to pool
the results again. The pooled OR estimate of each study
was calculated by the random-effects model.
The between-study heterogeneity was assessed by the
Chi square-test based Cochrane Q-test and I2 test. I2
values of 25%, 50%, and 75% were nominally assigned as
low, moderate, and high estimates. Departure from
Hardy-Weinberg equilibrium (HWE) in controls was
tested by the Chi-square test. Subgroup analyses were
conducted by ethnicity, calciuria level, and age group.
Sensitivity analyses were performed by excluding the
studies not in HWE and the studies with low quality, re-
spectively. Funnel plot was used to assess potential pub-
lication bias. Publication bias was also investigated
statistically via Egger’s test [36].
All statistical tests were performed by using STATA 11.0
software (Stata Corporation, College Station, TX). A P
value < 0.05 was considered statistically significant, except
for test of heterogeneity where a level of 0.10 was used.
Results
Study characteristics
Figure 1 outlines our study selection process. A total of
218 articles were identified after an initial search. Fifty-
Figure 1 Flow of study identification, inclusion, and exclusion.
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and abstracts, 127 articles were removed owing to ab-
stracts, reviews, non-clinical studies, not case–control
studies, and irrelevant to urolithiasis or VDR polymor-
phisms. After reading the full texts of the remaining 32
articles, 9 articles were excluded due to irrelevant to
urolithiasis risk, no useful data, and reduplicate study.
Finally, a total of 23 case–control studies met our inclu-
sion criteria. There were 11 studies on ApaI, 8 on BsmI,
14 on FokI, 13 studies on TaqI. Four studies reported
the haplotype of ApaI and TaqI polymorphisms. There
were 14 studies of Asians and 9 studies of Caucasians.
Seventeen studies were performed in adults, 3 in chil-
dren, and 1 did not offer detailed information. Three
studies only included patients with hypercalciuria, 6
studies included hypercalciuria patients partly and the
data for these patients could be extracted, and 14 studies
did not report detailed information. Quality scores for
the each study ranged from 3 to 6. The characteristics of
each study are presented in Table 1.
Quantitative data synthesis
VDR ApaI polymorphism
Eleven studies determined the association between ApaI
polymorphism and urolithiasis risk. Total sample sizes
in urolithiasis and control groups were 1584 and 1853.
The estimated OR1, OR2 and OR3 were 1.47, 1.30, and
1.04, respectively (Table 2). These estimates suggested a
dominant genetic model, and therefore AA and aA were
combined and compared with aa. As shown in Figure 2,
the pooled OR was 1.34 (95% CI 1.11 – 1.60, P = 0.002).
In the subgroup analysis by ethnicity, a significant asso-
ciation was found among Asians (OR = 1.43, 95% 1.16 –
1.75, P < 0.001) but not among Caucasians (OR = 1.08,
95% 0.74 – 1.57, P = 0.69). Subgroup analysis was also
performed according to the calciuria level. However, nosignificant increased risk of urolithiasis was found
among hypercalciuric patients (OR = 1.24, 95% CI 0.86 –
1.81, P = 0.25) (Table 2). In the subgroup analysis by age
group, a significant association was observed among
adults (OR = 1.30, 95% 1.04 – 1.62, P = 0.02). Sensitivity
analysis was performed by excluding the studies that did
not show HWE. The result was statistically significant
(OR = 1.30, 95% CI 1.04 – 1.62, P = 0.02). Sensitivity ana-
lysis was also performed by excluding the low quality
studies. The result was similar (OR = 1.34, 95% CI 1.09 –
1.66, P = 0.006). The shape of the funnel plot showed
symmetric (Figure 3). Egger’s test did not indicate sig-
nificant publication bias (P = 0.914).
VDR BsmI polymorphism
Eight studies (1210 cases and 1160 controls) that identi-
fied the association between VDR BsmI polymorphism
and urolithiasis risk were included in this meta-analysis.
The estimated OR1, OR2 and OR3 were 1.79, 1.85, and
0.96, respectively (Table 2). These estimates suggested a
dominant genetic model. The pooled OR was 1.81 (95%
CI 1.03 – 3.17, P = 0.04) (Figure 4). In the subgroup ana-
lysis by ethnicity, a marginally significant association was
found among Caucasians (OR = 2.43, 95% CI 1.02 –
5.80, P = 0.05) but not among Asians (OR 1.21, 95% CI
0.67 – 2.32, P = 0.49) (Table 2). In addition, subgroup
analysis in hypercalciuric patients showed significant in-
creased risk of urolithiasis (OR 2.43, 95% CI 1.36 – 4.35,
P = 0.003). In the stratified analysis by ethnicity, no sig-
nificant association was found among adults (OR 0.80,
95% CI 0.96 – 3.38, P = 0.07). However, sensitivity ana-
lyses conducted by excluding the studies not in HWE or
low quality studies did not find the significant associ-
ation between VDR BsmI polymorphism and urolithiasis
risk (Table 2). No publication bias was detected by fun-
nel plot (Figure 5) and Egger’s test (P = 0.461).












scoreFirst author Year Country Ethnicity Composition (HWE)
Ruggiero [10] 1999 Italy Caucasian Adult Mixed* NA 27 150 BsmI (No) PCR-RFLP 4
Jackman [11] 1999 USA Caucasian NA All Calcium 17 37 TaqI (No) PCR-RFLP 3
Chen a [12] 2001 China Asian Adult NA Calcium 124 90 BsmI (No) PCR-RFLP 4
Chen b [13] 2001 China Asian Adult NA Calcium 146 90 FokI (Yes) PCR-RFLP 4
Nishijima [14] 2002 Japan Asian Adult NA Calcium 83 83 ApaI (Yes), TaqI (Yes) PCR-RFLP 5
Mossetti [15] 2003 Italy Caucasian Adult NA Calcium 220 114 BsmI (Yes), TaqI (No) PCR-RFLP 5
Ozkaya [16] 2003 Turkey Caucasian Children All Calcium 64 90 ApaI (No), BsmI (Yes),
TaqI (Yes)
PCR-RFLP 4
Wang a [17] 2003 China Asian Adult Mixed* Calcium 150 80 ApaI (Yes), FokI (Yes),
TaqI (Yes)
PCR-RFLP 3
Relan [18] 2004 India Asian Adult Mixed* Calcium 150 100 BsmI (No), FokI (No) PCR-RFLP 3
Rendina [19] 2004 Italy Caucasian Adult All Calcium 159 124 ApaI (Yes), FokI (Yes) PCR-RFLP 6
Hu [20] 2004 China Asian Adult Mixed* Calcium 186 90 ApaI (Yes), FokI (Yes),
TaqI (Yes)
PCR-RFLP 5
Bid a [21] 2005 India Asian Adult Mixed* Calcium 138 166 FokI (No) PCR-RFLP 4
Bid b [22] 2005 India Asian Children NA Calcium 50 60 FokI (Yes) PCR-RFLP 5
Gunes [23] 2006 Turkey Caucasian Adult NA Calcium 110 150 ApaI (Yes), BsmI (Yes),
TaqI (Yes)
PCR-RFLP 6
Liu [24] 2007 China Asian Adult NA Calcium 235 231 FokI (Yes) PCR-RFLP 6
Moyano [25] 2007 Spain Caucasian Adult NA Calcium 51 21 ApaI (Yes), BsmI (Yes),
TaqI (Yes)
PCR-RFLP 3
Seyhan [26] 2007 Turkey Caucasian Children Mixed* Calcium 80 40 TaqI (No) PCR-RFLP 4
Wang b [27] 2009 China Asian Miexd NA Calcium 90 90 ApaI (No), FokI (No) PCR-RFLP 5
Mittal [28] 2010 India Asian Adult NA NA 125 150 ApaI (Yes), FokI (No),
TaqI (No)
PCR-RFLP 5
Seo [29] 2010 Korea Asian Miexd NA Calcium 102 535 ApaI (No), FokI (No),
TaqI (No)
PCR-RFLP 5
Basiri [30] 2012 Iran Caucasian Adult NA Calcium 106 109 FokI (No), TaqI (No) PCR-SSCP 5
Wang c [31] 2012 China Asian Adult NA Calcium 464 450 ApaI (Yes), BsmI (Yes),
FokI (Yes), TaqI (Yes)
PCR-RFLP 6
Ruan [32] 2012 China Asian Adult NA Calcium 169 156 FokI (No) PCR-RFLP 4
*Data for hypercalciuria patients could be extracted.
HWE, Hardy-Weinberg equilibrium; PCR, polymerase chain reaction; RFLP, restriction fragment length polymorphism; SSCP, single-strand conformational
polymorphism; NA, not available.
Zhang et al. BMC Medical Genetics 2013, 14:104 Page 4 of 14
http://www.biomedcentral.com/1471-2350/14/104VDR FokI polymorphism
For the VDR FokI polymorphism, fourteen studies includ-
ing 2266 cases and 2418 controls were included in this
meta-analysis. OR1, OR2, and OR3 were 1.59, 1.38, and
1.04, respectively. These estimates suggested a dominant
genetic model. Therefore, the original grouping was col-
lapsed, and ff and fF were combined, in accordance with a
dominant model, into a f carrier group, the latter of which
was compared with the FF genotype group. The pooled
OR was 1.48 (95% CI 1.03 – 2.12, P = 0.03) (Figure 6). In
the subgroup analysis by ethnicity, no significant associ-
ation was found among Asians (OR = 1.32, 95% CI 0.94 –
1.86, P = 0.11) (Table 2). In the subgroup analysis by the
calciuria level, there was still no significant associationbetween VDR FokI polymorphism and urolithiasis risk in
patients with hypercalciuria (OR = 1.15, 95% CI 0.81 –
1.63, P = 0.43) (Table 2). Statistically significant increased
urolithiasis risk was observed among adults group (OR =
1.71, 95% CI 1.14 – 2.56, P = 0.009). Sensitivity analyses
found that the significant result was altered when the low
quality studies or studies with Hardy-Weinberg disequilib-
rium were omitted (Table 2). The shape of the funnel plot
seemed symmetrical (Figure 7). Egger’s test did not show
evidence of publication bias (P = 0.081).
VDR TaqI polymorphism
Thirteen studies including 1744 patients and 1944 con-
trols addressed the association between VDR TaqI
Table 2 Summary of different comparative results
Sample size No. of
studies
Test of association Heterogeneity
Polymorphisms Study Case Control OR (95% CI) Z P Value Model χ2 P Value I2 (%)
ApaI
AA vs. aa Overall 846 1048 11 1.47 (1.11-1.94) 2.66 0.008 R 13.03 0.220 23.0
aA vs. aa Overall 1059 1368 11 1.30 (1.06-1.60) 2.54 0.010 R 10.98 0.360 9.0
AA vs. aA Overall 1263 1290 11 1.04 (0.76-1.43) 0.25 0.810 R 26.31 0.003 62.0
AA + aA vs. aa Overall 1584 1853 11 1.34 (1.11-1.60) 3.12 0.002 R 7.49 0.680 0.0
AA + aA vs. aa Asian 1200 1468 7 1.43 (1.16-1.75) 4.57 <0.001 R 4.57 0.600 0.0
AA + aA vs. aa Caucasian 384 385 4 1.08 (0.74-1.57) 0.40 0.690 R 1.32 0.730 0.0
AA + aA vs. aa Hypercalciuria 295 262 4 1.24 (0.86-1.81) 1.15 0.250 R 3.10 0.380 3.0
AA + aA vs. aa Adult 1328 1148 8 1.30 (1.04-1.62) 2.33 0.020 R 3.99 0.780 0.0
AA + aA vs. aa HWE 1328 1148 8 1.30 (1.04-1.62) 2.33 0.020 R 3.99 0.780 0.0
AA + aA vs. aa High quality 1319 1662 8 1.34 (1.09-1.66) 2.75 0.006 R 7.41 0.390 6.0
BsmI
bb vs. BB Overall 841 855 8 1.79 (0.98-3.26) 1.89 0.060 R 18.93 0.008 63.0
bB vs. BB Overall 611 609 8 1.85 (1.03-3.32) 2.05 0.040 R 21.94 0.003 68.0
bb vs. bB Overall 966 856 8 0.96 (0.77-1.20) 0.33 0.740 R 5.01 0.660 0.0
bb + bB vs. BB Overall 1210 1160 8 1.81 (1.03-3.17) 2.07 0.040 R 23.82 0.001 71.0
bb + bB vs. BB Asian 738 640 3 1.21 (0.67-2.32) 0.69 0.490 R 3.10 0.210 36.0
bb + bB vs. BB Caucasian 472 520 5 2.43 (1.02-5.80) 2.00 0.050 R 19.52 <0.001 80.0
bb + bB vs. BB Hypercalciuria 123 340 3 2.43 (1.36-4.35) 2.99 0.003 R 1.99 0.370 0.0
bb + bB vs. BB Adult 1146 1070 7 1.80 (0.96-3.38) 1.83 0.070 R 23.65 <0.001 75.0
bb + bB vs. BB HWE 909 820 5 1.36 (0.87-2.13) 1.35 0.180 R 4.90 0.300 18.0
bb + bB vs. BB High quality 794 709 3 1.15 (0.75-1.72) 0.66 0.510 R 1.01 0.600 0.0
FokI
ff vs. FF Overall 1144 1243 14 1.59 (1.08-2.35) 2.34 0.020 R 47.26 <0.001 72.0
fF vs. FF Overall 1647 1809 14 1.38 (0.96-2.00) 1.72 0.090 R 64.13 <0.001 80.0
ff vs. fF Overall 1741 1804 14 1.04 (0.74-1.45) 0.22 0.830 R 56.68 <0.001 77.0
ff + fF vs. FF Overall 2266 2418 14 1.48 (1.03-2.12) 2.12 0.030 R 68.26 <0.001 81.0
ff + fF vs. FF Asian 2005 2188 12 1.32 (0.94-1.86) 1.62 0.110 R 44.62 <0.001 75.0
ff + fF vs. FF Hypercalciuria 324 560 5 1.15 (0.81-1.63) 0.79 0.430 R 1.42 0.840 0.0
ff + fF vs. FF Adult 2024 1743 11 1.71 (1.14-2.56) 2.61 0.009 R 59.01 <0.001 83.0
ff + fF vs. FF HWE 1390 1125 7 1.05 (0.83-1.33) 0.39 0.700 R 8.54 0.200 30.0
ff + fF vs. FF High quality 1513 1348 7 1.34 (0.83-2.16) 1.19 0.230 R 53.59 <0.001 85.0
TaqI
tt vs. TT Overall 1144 1478 13 1.24 (0.92-1.68) 1.40 0.160 R 12.19 0.430 2.0
tT vs. TT Overall 1558 1786 13 1.33 (1.04-1.70) 2.28 0.020 R 21.41 0.040 44.0
tt vs. Tt Overall 806 624 13 0.92 (0.61-1.38) 0.40 0.690 R 21.56 0.040 44.0
tt + tT vs. TT Overall 1744 1944 13 1.30 (1.08-1.55) 2.79 0.005 R 13.54 0.330 11.0
tt + tT vs. TT Asian 1110 1386 6 1.39 (1.11-1.73) 2.87 0.004 R 4.32 0.500 0.0
tt + tT vs. TT Caucasian 644 558 7 1.21 (0.84-1.72) 1.02 0.310 R 10.06 0.120 40.0
tt + tT vs. TT Hypercalciuria 176 183 5 1.56 (1.06-2.31) 2.24 0.030 R 2.47 0.650 0.0
tt + tT vs. TT Adult 1481 1244 9 1.34 (1.05-1.71) 2.35 0.020 R 12.71 0.120 37.0
tt + tT vs. TT HWE 1098 964 7 1.36 (1.07-1.77) 2.51 0.010 R 7.44 0.280 19.0
tt + tT vs. TT High quality 1392 1676 8 1.27 (1.05-1.54) 2.43 0.010 R 9.23 0.240 24.0
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Table 2 Summary of different comparative results (Continued)
ApaI-TaqI haplotype
At vs. aT Overall 830 1207 4 1.35 (1.09-1.68) 2.71 0.007 R 2.91 0.410 0.0
At vs. aT Asian 644 961 3 1.53 (1.17-2.00) 3.14 0.002 R 0.35 0.840 0.0
At vs. aT Adult 752 806 3 1.36 (1.03-1.80) 2.16 0.030 R 2.90 0.230 31.0
vs., versus; HWE, Hardy-Weinberg equilibrium; R, random-effects model.
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and OR3 were 1.24, 1.33, and 0.92, respectively. These
pooling estimates suggested a dominant genetic model.
The pooled OR in the dominant genetic model was 1.30
(95% CI 1.08 – 1.55, P = 0.005) (Figure 8). In the strati-
fied analysis, statistically significant increased urolithiasis
risk was observed among Asians (OR = 1.39, 95% CI
1.11 – 1.73, P = 0.004) but not Caucasians (OR = 1.21,
95% CI 0.84 – 1.72, P = 0.31). Furthermore, patients with
hypercalciuria had a significant increase of the risk of
developing urolithiasis (OR = 1.56, 95% CI 1.06 – 2.31,
P = 0.03). In addition, significantly increased urolithiasis
risks were found among adults (OR = 1.34, 95% CI 1.05 –
1.71, P = 0.02). Sensitivity analysis did not change theFigure 2 Meta-analysis for the association between urolithiasis risk anresult (Table 2). The funnel plot appeared to be symmet-
rical (Figure 9). Egger’s test were performed to esti-
mate the publication bias. Publication bias was not
observed (P = 0.122).
VDR ApaI-TaqI haplotype
In 4 out of 23 studies, the role of VDR ApaI-TaqI
haplotype in urolithiasis risk was analyzed. The sam-
ple sizes in case group and control group were 830
and 1207, respectively. Carling et al. [37] reported that the
At haplotype displayed higher levels of mRNA expression
than aT haplotype. Thus, the effect of these two hap-
lotypes on the risk of urolithiasis was evaluated in
this meta-analysis. As shown in Figure 10, the poolingd the VDR ApaI polymorphism.
Figure 3 Funnel plot for publication bias in selection of studies on the VDR ApaI polymorphism.
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oping urolithiasis in subjects with the At haplotype
(OR = 1.35, 95% CI 1.09 – 1.68, P = 0.007). In the sub-
group analysis by ethnicity, a significant association
was found among Asians (OR = 1.53, 95% CI 1.17 –Figure 4 Meta-analysis for the association between urolithiasis risk an2.00, P = 0.002). In the stratified analysis of age group,
we also found a significant association (OR = 1.36,
95% CI 1.03 – 1.80, P = 0.03). Symmetrical funnel plot
was obtained (Figure 11). Publication bias was not
observed (P = 0.887).d the VDR BsmI polymorphism.
Figure 5 Funnel plot for publication bias in selection of studies on the VDR BsmI polymorphism polymorphism.
Figure 6 Meta-analysis for the association between urolithiasis risk and the VDR FokI polymorphism.
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Figure 7 Funnel plot for publication bias in selection of studies on the VDR FokI polymorphism.
Figure 8 Meta-analysis for the association between urolithiasis risk and the VDR TaqI polymorphism.
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Figure 9 Funnel plot for publication bias in selection of studies on the VDR TaqI polymorphism.
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This present meta-analysis systematic investigated the
associations between VDR polymorphisms and urolithia-
sis risk. We found that ApaI polymorphism was a risk
factor for developing urolithiasis. This result indicated
that the carriers of the AA or Aa genotype had a 34% in-
creased urolithiasis risk compared to those individuals
with the aa genotype. Sensitivity analysis did not change
this result, suggesting the solidity of our result. In theFigure 10 Meta-analysis for the association between urolithiasis risk astratified analysis by ethnicity, the significant association
was found in Asian population but not in Caucasian
population. In addition, BsmI and FokI polymorphisms
were also significantly associated with urolithiasis risk in
the overall population. However, results from sensitivity
analyses suggested that these results were not statistically
robust. Therefore, these results should be interpreted with
caution and more studies are needed to evaluate the effect
of BsmI and FokI polymorphisms on urolithiasis risk.nd the VDR ApaI-TaqI haplotype.
Figure 11 Funnel plot for publication bias in selection of studies on the VDR ApaI-TaqI haplotype.
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harbored b allele may have increased urolithiasis risk. As
for the TaqI polymorphism, a significant association was
observed between this polymorphism and the risk of
urolithiasis. Sensitivity analyses further strengthened
the validity of this result. When subgroup analysis was
conducted according to the ethnicity, the significant asso-
ciation was showed in Asians and lack of a significant as-
sociation was detected in Caucasian population. In the
hypercalciuria subgroup analysis, a 56% increased risk of
urolithiasis was found in patients with hypercalciuria. Col-
lectively, these results suggested that VDR BsmI and TaqI
polymorphisms may play unique roles in the etiology of
hypercalciuric urolithiasis. However, because the number
of studies included in the hypercalciuria subgroup ana-
lyses was small, the results lacked sufficient reliability to
confirm these associations in a definitive manner. Thus,
future studies with larger sample sizes are needed to con-
firm our results. Furthermore, we assessed the association
between the haplotypes of the ApaI and TaqI polymor-
phisms and urolithiasis risk. The result from this meta-
analysis suggested that At haplotype may play a role in
urolithiasis susceptibility, especially in Asians. Taken to-
gether, our results exhibited significant associations be-
tween ApaI and TaqI polymorphisms and urolithiasis risk
in Asian population but not in Caucasian population.
There are at least four reasons to explain the ethnic differ-
ence. First, the number of Caucasian patients was small.
There were only 384 and 644 Caucasian patients for these
two polymorphisms, respectively. It was therefore possible
that the observed ethnic difference was due to chance.
More studies with Caucasian population are required to
validate the effect of ethnic differences. Second, higher
heterogeneity was observed in the Caucasians subgroup
(I2 = 40%) but not in the Asians subgroup (I2 = 0%) in TaqIpolymorphism. This may distort the result. Third, urolith-
iasis is a complex disease. Both genetic and environmental
factors could affect the risk of urolithiasis in different pop-
ulations. It is possible that different urolithiasis risks in
Asians and Caucasians were due to exposure to various
environmental factors. To data, there was no reported
study which was performed to assess the effect of VDR-
environment interactions on urolithiasis risk in different
ethnicities and regions. Therefore, epidemiologic studies
should be designed to examine these associations in the
future. Fourth, ethnic difference in the VDR gene allele
frequencies may also result in this difference. For example,
the A allele of the ApaI, occured with lower frequency in
Caucasians when compared to Asians, while the t allele of
the TaqI had a higher frequency in Asians compared to
Caucasians [38]. We also performed subgroup analyses by
age group. There were still significant associations in the
adults group except in BsmI polymorphism. These results
indicated that these polymorphisms were significantly as-
sociated with increased urolithiasis risk in adults. We did
not evaluate the associations between VDR polymor-
phisms and urolithiasis risk in children due to insufficient
data. More studies using children population are needed
to determine the associations between VDR polymor-
phisms and urolithiasis risk.
A considerable weight of evidence supporting a role
for VDR in urolithiasis was derived from GHS rats. Ex-
perimental studies using GHS rats showed increased
levels of VDR in intestine, bones and kidneys [6,39].
Moreover, Karnauskas et al. [40] found that prolongation
of VDR half-life increased VDR tissue levels and medi-
ated VDR-regulated genes that led to hypercalciuria. Re-
cently, using microRNA targeting VDR, Xi and colleagues
silenced the VDR gene in the kidneys of GHS rats [41].
They demonstrated VDR knockdown in the kidney can
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vanilloid receptor subtype 5 (TRPV5) in GHS rats [41].
Previous study found that mice lacking TRPV5 exhibited
reduced calcium reabsorption, which caused severe hyper-
calciuria [42]. In addition, hypercalciuria increased the risk
for calcium oxalate nephrolithiasis and occurred in up to
50% of nephrolithiasis patients [43,44]. Therefore, high
VDR level might contribute to the development of urolith-
iasis. VDR was one of the most studied candidate genes
for urolithiasis. Carling et al. [37] showed that the individ-
uals exhibiting the BB, AA, or tt genotypes had signifi-
cantly higher VDR levels than those with homozygous for
the b, a, or T alleles. They also found those exhibiting the
baT haplotype demonstrated a relative lower VDR mRNA
level than subjects with non-baT haplotype [37]. Further-
more, Yamagata et al. [45] showed the VDR mRNA levels
of allele t were significantly higher than those of allele T in
peripheral blood mononuclear cell (PBMC). Thus, it is
biologically plausible that subjects with the B, A, or t al-
leles may have increased risk of urolithiasis. Our findings
supported this speculation and the At haplotype carriers
had increased urolithiasis risk than the aT haplotype car-
riers. However, we found that b allele carriers, but not B
allele carriers, were associated with urolithiasis, although
this result was not robust. Notablely, hypercalciuric pa-
tients with b allele were seemed to have higher urolithiasis
risk in the subgroup analysis. This result agreed with the
report of Ferreira et al. [46], who also found that bb
homozygous for VDR polymorphism was overrepresented
in hypercalciuric stone formers. Additionally, Relan and
co-authors reported that subjects with the bb genotype
exhibited a higher urinary calcium excretion than the BB
genotype [18]. Ruggiero et al. [10] found the similar
phenomenon. The altered function of the VDR gene for
the BsmI polymorphism may be associated with higher
urinary calcium excretion. Hypercalciuria was a risk factor
of urolithiasis. It was thus possible that b allele carriers
may have higher urolithiasis risk than B allele carriers. As
for the FokI polymorphism, Jurutka et al. [47] suggested
that F variant possessed elevated transcriptional activity
compared with the f variant. However, there was no differ-
ence between these two variants on the VDR expression
[47]. Results from our study suggested that there was a
significant association between f variant and urolithiasis.
But the mechanism was unknown. The functional studies
of VDR FokI polymorphism are still required. In addition,
more studies are needed to confirm our results.
Our meta-analysis included a total of 23 case–control
studies with 3046 cases and 3206 controls, while a previ-
ous meta-analysis by Lin et al. [48] only included 17
case–control studies with 2046 cases and 2303 controls.
They found significant associations between FokI and
TaqI polymorphisms and urolithiasis risk. However, we
found ApaI and TaqI polymorphisms were significantlyassociated with urolithiasis risk. More case–control stud-
ies were included in our meta-analysis than Lin’s study.
Therefore, our study may be more powerful and the
conclusion might be more reliable. This reason might ex-
plain the difference between these two meta-analyses. In
addition, our study had some advantages. First, Lin and
coworkers tested multiple genetic models, including allelic
comparison, a dominant model, and a recessive model.
However, they did not correct for multiple comparisons
or give biologic rationale for the choice of these genetic
models. When the underlying genetic model is unknown,
it is better to use pairwise comparisons of the three geno-
types to find the best genetic model [34]. We used this
method to avoide the problem of multiple comparisons.
Second, it was the first time studying the VDR-hypercalci-
uria interactions on urolithiasis risk. Third, we explored
the haplotype effect of ApaI and TaqI polymorphisms on
the susceptibility to urolithiasis. Finally, the methodo-
logical issues for meta-analysis, such as, quality assess-
ment was well investigated.
We should point out the importance of heterogeneity
and publication bias, which might influence the results
of meta-analysis. In our study, significant heterogeneity
was found in the BsmI and FokI polymorphisms. Sub-
group analysis was used to explore the sources of het-
erogeneity. After subgroup analysis by the calciuria level,
the heterogeneity was effectively disappeared in hyper-
calciuric patients. Thus, it could be presumed that the
relatively large heterogeneity mainly resulted from the
calciuria level. In addition, funnel plot and Egger’s tests
were used to find potential publication bias. No signifi-
cant publication bias was detected.
Some limitations of our study should be addressed.
First, the number of studies that were included in this
meta-analysis was moderate. It was possible that some
relevant published studies or unpublished studies with
negative results were missed. Second, all of the studies
were performed in Asians and Caucasians; thus, our re-
sults may be applicable only to these ethnic groups.
Third, this study did not address gene-gene and gene-
environment interactions, because insufficient informa-
tion could be extracted from the original publications.
Fourth, the data of the stone types and biochemical pro-
files was not showed in our meta-analysis because of in-
sufficient information from the primary publications.
Finally, we could not investigate the association between
the haplotypes of the ApaI, BsmI, and TaqI polymor-
phisms and urolithiasis risk.
Conclusions
To our knowledge, this was the most comprehensive
meta-analysis to assess the relationship between the
VDR polymorphisms and urolithiasis susceptibility. Our
results indicated that the ApaI and TaqI polymorphisms
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http://www.biomedcentral.com/1471-2350/14/104were associated with the risk of urolithiasis. Haplotype
analysis suggested that ApaI-TaqI haplotypes conferred
the susceptibility to urolithiasis. Future large-scale stud-
ies with more ethnic groups are needed to validate our
findings. Gene-gene and gene-environment interactions
should also be considered in future studies.
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